A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight

NCT07745504 · tracked via the Priya Life Science USA tracker

Sponsor

Novo Nordisk A/S

Phase

Phase 3

Started

2026-08-04

Last updated

2026-09-04

Condition(s) studied

OverweightObesity

Investigational drug(s) / intervention(s)

CagrilintidePlacebo cagrilintidePlacebo semaglutide

Cagrilintide: Cagrilintide will be administered subcutaneously.

Placebo cagrilintide: Placebo matched to cagrilintide will be administered subcutaneously.

Placebo semaglutide: Placebo matched to semaglutide will be administered subcutaneously.

Study summary

The purpose of this clinical study is to look at how well a study medicine called cagrilintide helps people living with excess body weight to lose weight. Participants will either get cagrilintide, the active study medicine being tested or placebo, a medicine that has no active medicine in it. Which treatment participants get is decided by chance. Cagrilintide is a new medicine under development that doctors cannot prescribe yet, but it has been tested in humans before. Participants will be in this clinical study for about 9 months.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion criteria: * Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study. * Male or female (sex assigned at birth, inclusive of all gender identities). * Age 18 years or above at the time of signing the informed consent. * Body mass index (BMI) greater than or equal to (\>=) 30.0 kilograms per square meter (kg/m\^2), or BMI \>= 27.0 kg/m\^2 with the presence of at least one weight related comorbidity including, but not limited to, hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease. Exclusion criteria: * History of Type 1 Diabetes (T1D) or Type 2 Diabetes (T2D). * Previous dosing of marketed or non-marketed amylin-based compounds. * Treatment, or intention to initiate treatment, with any medication prescribed for the indication of weight management within 180 days before screening.

Primary outcome measure(s)

Relative change in body weight — From baseline (week 0) to end of treatment (week 26)
Measured as percentage (%).

Trial sites (36)

Facility	City	Region	Status
Hope Clin Res & Wellness	Conyers	Georgia	Recruiting
East West Med Res Inst	Honolulu	Hawaii	Recruiting
Walgreens - Store 11760	Oak Park	Illinois	Not Yet Recruiting
Midwest Inst For Clin Res	Indianapolis	Indiana	Recruiting
The Alliance for Multispecialty Research LLC AMR	Lexington	Kentucky	Recruiting
PharmQuest	Greensboro	North Carolina	Recruiting
KDCILM, LLC & Accellacare US, Inc.	Wilmington	North Carolina	Recruiting
Coastal Carolina Res Ctr	North Charleston	South Carolina	Recruiting
Health Res of Hampton Roads	Newport News	Virginia	Recruiting
National Clin Res Inc.	Richmond	Virginia	Recruiting
Selma Medical Associates	Winchester	Virginia	Recruiting
General Hospital Of Athens Alexandra - Department of Endocrinology, Diabetes Center	Athens	Greece	Recruiting
General Hospital Of Athens G Gennimatas - Department of Endocrinology	Athens	Greece	Recruiting
General Hospital Venizeleio-Pananeio - Diabetic Clinic	Irakleio	Greece	Recruiting
Athens Medical Center S.A. (Iatriko Peristeriou) - Diabetes, obesity and cardiometabolic diseases department	Peristeri	Greece	Recruiting
Ippokratio General Hospital Of Thessaloniki - B' Internal Medicine clinic	Thessaloniki	Greece	Recruiting
St. Luke's Hospital S.A. - Endocrinology Department and Obesity Clinic	Thessaloniki	Greece	Recruiting
Stúdium Egészségház Kft.	Kalocsa	Bács-Kiskun county	Recruiting
Borbánya Praxis E.Ü. Kft.	Nyíregyháza	Szabolcs-Szatmar Varmegye	Recruiting
Trial Pharma Kft.	Kecskemét	Hungary	Recruiting
KomplexLabor Diagnosztika Kft.	Szeged	Hungary	Recruiting
ULS Do Oeste E.P.E. - Unidade Caldas da Rainha_CAMI - Unidade de Diabetes	Caldas da Rainha	Portugal	Recruiting
ULS Do Baixo Mondego, E.P.E. - HDFF_Serviço Cirurgia (Esp. Endocrinologia)	Figueira da Foz Municipality	Portugal	Recruiting
Hospital São Francisco, S.A_EECC	Leiria	Portugal	Recruiting
APDP - Associação Protectora dos Diabéticos de Portugal	Lisbon	Portugal	Recruiting
CVP Hospital Cruz Vermelha_Cardiologia	Lisbon	Portugal	Recruiting
ULS De Gaia/Espinho_H.Santos Silva_Endocrinologia	Vila Nova de Gaia	Portugal	Recruiting
Endocrinology, Diabetes and Metabolism Diseases Clinic	Belgrade	Serbia	Recruiting
Institute for Cardiovascular Diseases of Vojvodina - Sremska Kamenica	Kamenitz	Serbia	Recruiting
Clinical Centre Nis, Endocrinology, Diabetes and Metabolism	Niš	Serbia	Recruiting
University Clinical Centre Nis, Clinic for Cardiology	Niš	Serbia	Recruiting
Clin. Centre Vojvodina, Clin. endocr., diab. and met. dis.	Novi Sad	Serbia	Recruiting
Skånes Universitets Sjukhus	Lund	Sweden	Recruiting
Forsåker vårdcentral	Mölndal	Sweden	Recruiting
Örebro US - Överviktsenheten	Örebro	Sweden	Recruiting
Dalecarlia Clinical Research AB	Rättvik	Sweden	Recruiting

More Novo Nordisk A/S trials in the USA

A Research Study in Children Born Small and Who Stayed Small. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day Active, not recruiting

A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease Recruiting

AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss Active, not recruiting

AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight Starting soon

A Research Study to Evaluate the Safety of NNC4004-0002 When Given to Participants With Asymptomatic Hyperuricemia Recruiting

Other trials for the same condition

A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity Active, not recruiting

A Study of Eloralintide (LY3841136) in Female Participants With Obesity or Overweight Starting soon

Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes Recruiting

Study to Evaluate HM15275 in Obese or Overweight Subjects Without Diabetes Mellitus Active, not recruiting

A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07745504 on ClinicalTrials.gov ↗ ← All trials in the USA